SCHEMBL9892865

SCHEMBL9892865

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1nc2cc(Cl)ccc2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.64
CNR2 P34972 3/20 0.56
CNR1 P21554 1/20 0.55
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
ALDH1A1 P00352 3/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
HPGD P15428 1/20 0.49
ALOX12 P18054 1/20 0.49
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 2/20 0.45
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16238648 0.93 L3MBTL1 (0.68) L3MBTL1CNR2CNR1CASP3SENP8
SCHEMBL13257795 0.93 L3MBTL1 (0.68) L3MBTL1CNR2CNR1CASP3SENP8
SCHEMBL9892884 0.86 L3MBTL1 (0.68) L3MBTL1ALDH1A1LMNANPSR1MAPT
SCHEMBL13256792 0.86 L3MBTL1 (0.77) L3MBTL1CNR2CNR1CASP3SENP8
SCHEMBL16238601 0.86 L3MBTL1 (0.77) L3MBTL1CNR2CNR1CASP3SENP8
SCHEMBL16238573 0.82 L3MBTL1 (0.68) L3MBTL1CNR2CNR1LMNANPSR1
SCHEMBL13256793 0.82 L3MBTL1 (0.68) L3MBTL1CNR2CNR1LMNANPSR1
SCHEMBL20458169 0.82 L3MBTL1 (0.45) L3MBTL1CNR2CNR1CASP3SENP8
SCHEMBL13257160 0.80 L3MBTL1 (0.71) L3MBTL1CNR2CNR1ALDH1A1LMNA
SCHEMBL16239144 0.80 L3MBTL1 (0.71) L3MBTL1CNR2CNR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 L3MBTL1 4866/4885CNR2 1/4885CNR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.